Bionano Genomics, Inc. (NASDAQ:BNGO) is a life sciences company that focuses on genome analysis. It provides tools and services for genetic research, which are crucial for understanding genetic diseases and developing treatments. Bionano competes with other genomics companies in the rapidly growing field of genetic research and diagnostics.
On March 23, 2026, BNGO is set to release its quarterly earnings. Wall Street estimates a loss of $2.47 per share, while analysts predict a smaller loss of $1.40 per share. Revenue projections are close, with Wall Street expecting $7.88 million and analysts estimating $7.85 million. Previously, Bionano projected its revenue to be between $7.8 million and $8.0 million.
Bionano's stock is currently priced at $1.12. Despite a negative price-to-earnings (P/E) ratio of -0.16, the company maintains a price-to-sales ratio of 0.13. This means the stock is valued at 13 cents for every dollar of sales. The enterprise value to sales ratio is 0.28, reflecting the company's valuation relative to its revenue.
The company's financial health is mixed. The enterprise value to operating cash flow ratio is around -0.43, indicating negative cash flow. However, the debt-to-equity ratio is 0.15, suggesting low debt levels. The current ratio of 2.12 indicates good short-term financial health, with more than twice the current assets compared to liabilities.
Analyst Yi Chen from HC Wainwright and Co. maintains a Buy rating on BNGO, though the price target was reduced from $11 to $7 in November 2025. Bionano will host a conference call and webcast on March 23, 2026, to discuss its financial results and corporate progress. CEO Erik Holmlin will be involved, and the webcast will be available on the company's investor relations site.
